The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.
|Videos|May 26, 2017
Dr. Shain Discusses Emerging Agents in Multiple Myeloma
Author(s)Kenneth H. Shain, MD, PhD
Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses emerging agents in multiple myeloma.
Advertisement
Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses emerging agents in multiple myeloma.
Oprozomib, an oral agent, is an irreversible proteasome inhibitor that has shown good activity in highly refractory patients.
Additionally, there is marizomib, another proteasome inhibitor that is being looked at alone and in combinations. It still requires further study—but it is something exciting that is on the horizon, says Shain.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The CHMP opinion is backed by phase 3 MonumenTAL-3 data evaluating talquetamab plus daratumumab in relapsed/refractory multiple myeloma.
The top 5 OncLive TV videos of the week.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Pembrolizumab for Unresectable/Metastatic TMB-H Solid Tumors
2
Experts Tackle Key Questions on CDK4/6 Inhibition Across HR+ Breast Cancer Settings
3
Pembrolizumab Plus Enfortumab Vedotin Earns EC Approval in Resectable MIBC
4
Tolerability Remains a TROP2-Directed ADC Hurdle in EGFR-Mutated NSCLC
5